GlucoTrack, Inc. (NASDAQ:GCTK) Short Interest Update

GlucoTrack, Inc. (NASDAQ:GCTK) was the target of a large growth in short interest during the month of May. As of May 29th, there was short interest totaling 363,693 shares, a growth of 725.9% from the May 14th total of 44,035 shares. Based on an average daily volume of 750,364 shares, the short-interest ratio is presently 0.5 days. Approximately 5.9% of the shares of the company are short sold.

GlucoTrack Price Performance

NASDAQ GCTK opened at $0.41 on Friday. The stock has a 50-day simple moving average of $0.69 and a 200 day simple moving average of $2.25. The company has a debt-to-equity ratio of 0.08, a quick ratio of 0.85 and a current ratio of 0.85. The stock has a market capitalization of $2.57 million, a PE ratio of -0.02 and a beta of 0.72. GlucoTrack has a twelve month low of $0.29 and a twelve month high of $15.90.

Hedge Funds Weigh In On GlucoTrack

Several large investors have recently added to or reduced their stakes in the company. Ikarian Capital LLC acquired a new position in GlucoTrack in the 4th quarter valued at approximately $177,000. Boothbay Fund Management LLC acquired a new position in GlucoTrack in the 4th quarter valued at approximately $52,000. Finally, Bank of America Corp DE raised its holdings in GlucoTrack by 102,125.0% in the 2nd quarter. Bank of America Corp DE now owns 4,089 shares of the company’s stock valued at $25,000 after acquiring an additional 4,085 shares in the last quarter. Institutional investors and hedge funds own 10.92% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of GlucoTrack in a research report on Tuesday, April 21st. Wall Street Zen raised GlucoTrack to a “sell” rating in a research report on Saturday, May 30th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, GlucoTrack has an average rating of “Sell”.

About GlucoTrack

GlucoTrack, Inc, a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc and changed its name to GlucoTrack, Inc in November 2021. GlucoTrack, Inc was founded in 2001 and is based in Rutherford, New Jersey.